Forest Labs scoops up diabetes programs in $1.1B TransTech deal

Faced with the loss of major patent protection in 2012, Forest Laboratories is gambling $50 million upfront and promising more than a billion dollars more to in-license early-stage diabetes meds from High Point, NC-based TransTech Pharma. The licensing package includes TransTech's lead program--TTP399--which recently wrapped up its Phase I trial. And it includes other early-stage liver-selective Glucokinase Activators as well. Forest gains the commercial rights to the drugs in most of the...